Neurogene Inc. Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price
Neurogene Inc. (NGNE) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price of $27.06 per share for the 9-month period ending 2023-09-30, per its 10-Q filed 2023-11-14.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice · last filed 2023-11-14
- Neurogene Inc. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for the quarter ending 2023-03-31 was $4.86, a 42.96% decline year-over-year.
- Neurogene Inc. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for the quarter ending 2022-03-31 was $8.52, a 48.77% decline year-over-year.
- Neurogene Inc. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for the quarter ending 2021-03-31 was $16.63, a 1.66% decline year-over-year.
- Neurogene Inc. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for the quarter ending 2020-03-31 was $16.91, a 42.94% increase year-over-year.
- Neurogene Inc. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2022 was $7.10, a 2.87% decline from fiscal 2021.
- Neurogene Inc. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2021 was $7.31, a 53.41% decline from fiscal 2020.
- Neurogene Inc. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2020 was $15.69, a 80.14% increase from fiscal 2019.
- Neurogene Inc. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2019 was $8.71, a 40.75% decline from fiscal 2018.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|
| 2023-09-30 | $27.06 10-Q · filed 2023-11-14 | |||
| 2023-06-30 | $5.07 10-Q · filed 2023-08-10 | |||
| 2023-03-31 | $4.86 10-Q · filed 2023-05-08 | |||
| 2022-12-31 | $7.10 10-K · filed 2023-03-20 | |||
| 2022-09-30 | $7.86 10-Q · filed 2022-11-14 | |||
| 2022-06-30 | $7.87 10-Q · filed 2022-08-09 | |||
| 2022-03-31 | $8.52 10-Q · filed 2022-05-09 | |||
| 2021-12-31 | $7.31 10-K · filed 2022-03-01 | |||
| 2021-09-30 | $11.14 10-Q · filed 2021-11-04 | |||
| 2021-06-30 | $11.25 10-Q · filed 2021-08-05 | |||
| 2021-03-31 | $16.63 10-Q · filed 2021-05-12 | |||
| 2020-12-31 | $15.69 10-K · filed 2021-03-25 | |||
| 2020-09-30 | $15.65 10-Q · filed 2020-11-09 | |||
| 2020-06-30 | $15.83 10-Q · filed 2020-08-12 | |||
| 2020-03-31 | $16.91 10-Q · filed 2020-05-06 | |||
| 2019-12-31 | $8.71 10-K · filed 2020-03-12 | |||
| 2019-09-30 | $11.84 10-Q · filed 2019-11-13 | |||
| 2019-06-30 | $11.76 10-Q · filed 2019-08-01 | |||
| 2019-03-31 | $11.83 10-Q · filed 2019-05-07 | |||
| 2018-12-31 | $14.70 10-K · filed 2019-03-07 | |||
| 2018-09-30 | $14.86 10-Q · filed 2018-11-07 | |||
| 2018-06-30 | $14.98 10-Q · filed 2018-08-08 | |||
| 2018-03-31 | $13.42 10-Q · filed 2018-05-08 | |||
| 2017-12-31 | $12.29 10-K · filed 2018-03-12 | |||
| 2017-09-30 | $12.42 10-Q · filed 2017-11-08 | |||
| 2017-06-30 | $12.37 10-Q · filed 2017-08-08 | |||
| 2017-03-31 | $12.37 10-Q · filed 2017-05-09 | |||
| 2016-12-31 | $9.39 10-K · filed 2017-03-09 | |||
| 2016-09-30 | $9.39 10-Q · filed 2016-11-09 | |||
| 2016-06-30 | $9.39 10-Q · filed 2016-08-04 | |||
| 2016-03-31 | $12.25 10-Q · filed 2016-05-10 | |||
| 2015-12-31 | $9.58 10-K · filed 2016-03-14 | |||
| 2015-09-30 | $9.58 10-Q · filed 2015-11-10 | |||
| 2015-06-30 | $0.00 10-Q · filed 2015-08-06 | |||
| 2015-03-31 | $0.00 10-Q · filed 2015-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |